Statements (57)
Predicate | Object |
---|---|
gptkbp:instance_of |
gptkb:pharmaceuticals
|
gptkbp:application |
topical
apply to base of eyelashes |
gptkbp:approves |
gptkb:2001
gptkb:FDA |
gptkbp:available_in |
gptkb:various_countries
|
gptkbp:brand |
gptkb:Latisse
|
gptkbp:clinical_trial |
Phase 3
studied for efficacy showed significant eyelash growth |
gptkbp:clinical_use |
gptkb:cosmetics
|
gptkbp:contraindication |
hypersensitivity to bimatoprost
|
gptkbp:demographics |
adults
|
gptkbp:dosage_form |
once daily
|
gptkbp:duration |
at least 8 weeks for results
|
gptkbp:form |
eyelash serum
|
https://www.w3.org/2000/01/rdf-schema#label |
Latisse
|
gptkbp:ingredients |
gptkb:water
gptkb:bimatoprost gptkb:edetate_disodium gptkb:benzalkonium_chloride citric acid preservatives sodium chloride sodium phosphate prostaglandin analog |
gptkbp:invention |
patented
|
gptkbp:is_effective_against |
promotes eyelash growth
|
gptkbp:manufacturer |
gptkb:Allergan
|
gptkbp:marketed_as |
cosmetic use
eyelash enhancement product |
gptkbp:packaging |
bottle with applicators
|
gptkbp:price |
varies by pharmacy
|
gptkbp:related_products |
gptkb:Lumigan
|
gptkbp:requires |
gptkb:true
|
gptkbp:safety_features |
generally safe
|
gptkbp:service_frequency |
daily
|
gptkbp:side_effect |
allergic reaction
dry eyes eye irritation redness of the eye darkening of eyelid skin eyelash changes increased brown pigmentation of iris |
gptkbp:storage |
room temperature
|
gptkbp:submission_deadline |
evening
|
gptkbp:suitable_for |
pregnant women
nursing mothers under 16 years old people with allergies to ingredients people with active eye conditions people with certain eye surgeries people with eye infections |
gptkbp:used_for |
hypotrichosis
|
gptkbp:user_feedback |
generally positive
|
gptkbp:bfsParent |
gptkb:Allergan
|
gptkbp:bfsLayer |
5
|